Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.01M, -90.6% YoY · Filed Aug 12, 2026
Arbutus Biopharma Corp (ABUS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.0 million and a net loss of $5.1 million. As of Jun 30, 2026 it held $92.6 million in cash and investments and $514,000 in total debt.
Revenue
$1.01M
-90.6% vs year-ago quarter
Net income
$-5.14M
-303.8% vs year-ago quarter
Operating cash flow
$-6.02M
+61.8% vs year-ago quarter
Free cash flow
$-4.68M
+55.0% vs year-ago quarter
EPS
$-0.03
-400.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
197.85M
+3.2% vs year-ago quarter
Net cash
$92.11M
Q2 FY2026
Operating margin
82.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABUS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Warminster, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1447028
- Former names
- TEKMIRA PHARMACEUTICALS CORP (until Aug 3, 2015); TEKMIRA PHARMACEUTICALS Corp (until Aug 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.0M | $179.1M | $1.1M | $529,000 | $10.7M |
| Operating income | -$6.0M | $168.9M | -$5.3M | -$8.7M | $1.5M |
| Net income | -$5.1M | $169.7M | -$3.8M | -$7.7M | $2.5M |
| Diluted EPS | -$0.03 | $0.87 | -$0.02 | -$0.04 | $0.01 |
| Operating cash flow | -$6.0M | -$8.1M | -$4.7M | -$5.8M | -$15.7M |
| Free cash flow | — | — | -$4.7M | -$5.8M | -$15.7M |
| Total assets | $274.0M | $277.2M | $94.6M | $97.7M | $103.3M |
| Total liabilities | $15.3M | $17.0M | $18.0M | $20.3M | $20.3M |
| Stockholders' equity | $258.7M | $260.2M | $76.6M | $77.4M | $83.0M |
| Cash and investments | $92.6M | $95.2M | $91.5M | $93.7M | $98.1M |
| Total debt | $514,000 | $631,000 | $746,000 | $922,000 | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Other events
|
Aug 21, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Agreement ended, Officer or director change, Other events
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 26, 2026 |
All 1000 Arbutus Biopharma Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.